Antigenics announces excellent results of AG-707 genital herpes vaccine Antigenics announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2 , the virus that causes genital herpes, in infected sufferers generisk cialis cialisinorge.com . Produced by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells. Recent data suggest both these arms of immunity are needed for effective treatment of genital herpes.D., study professor and investigator of Medicine, Laboratory Medicine and Global Health Medication, University of Washington.

Prescribers will have greater versatility to optimize medical response and tolerability when working with Aptiom to deal with people with partial-beginning point seizures, mentioned Antony Loebel, MD, executive vice president and chief medical officer of Sunovion. John Stern, MD, director of the Epilepsy Clinical System and professor in the UCLA Section of Neurology, observed that about one-third of the around 3 million epilepsy individuals in the United States do not completely react to current treatment approaches. Aptiom may be the newest addition to the dibenzazepine carboxamide class of AEDs. Side effects connected with Aptiom include nervous system problems such as dizziness, sleepiness, and vision problems.